<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1938">
  <stage>Registered</stage>
  <submitdate>22/04/2008</submitdate>
  <approvaldate>22/04/2008</approvaldate>
  <nctid>NCT00667082</nctid>
  <trial_identification>
    <studytitle>NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma</studytitle>
    <scientifictitle>NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NPI-0052-103</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-Small Cell Lung Cancer</healthcondition>
    <healthcondition>Pancreatic Cancer</healthcondition>
    <healthcondition>Melanoma</healthcondition>
    <healthcondition>Lymphoma</healthcondition>
    <healthcondition>Multiple Myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Pancreatic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - NPI-0052 (marizomib) + vorinostat

Experimental: NPI-0052 + Vorinostat Dose-Escalation - 4 dose-escalation cohorts


Treatment: drugs: NPI-0052 (marizomib) + vorinostat
NPI-0052 IV injection over 1 to 10 minutes at doses ranging from 0.15 to 0.7 mg/m2 on Days 1, 8, and 15 of each 28-day Cycle
Oral vorinostat 300 mg was administered with food on Days 1 to 16 of each 28-day Cycle

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the Maximum tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the combination NPI-0052 and Vorinostat</outcome>
      <timepoint>continuously</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the pharmacokinetics and pharmacodynamics of NPI-0052 and vorinostat</outcome>
      <timepoint>continuous</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the safety and toxicity profile of the combination of NPI-0052 and vorinostat</outcome>
      <timepoint>continuous</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the anti-tumor activity of NPI-0052 and vorinostat</outcome>
      <timepoint>continuous</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Karnofsky Performance Status (KPS) at 70% or more.

          2. Non-small cell lung cancer, pancreatic adenocarcinoma, melanoma or lymphoma for which
             a standard, approved therapy is not available. Patients must have lesions that are
             evaluable by RECIST criteria.

          3. All Adverse Events of any prior chemotherapy, surgery, or radiotherapy, must have
             resolved to CTCAE (v. 3.0) Grade 1 or less(except for hemoglobin).

          4. Adequate bone marrow, renal, liver function.

          5. Signed informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Recent administration of chemotherapy, biological, immunotherapy or investigational
             agent, major surgery, or radiotherapy.

          2. Intrathecal therapy.

          3. Known brain metastases.

          4. Significant cardiac disease.

          5. Prior treatment with vorinostat or NPI-0052, or other HDACi (including valproic acid)
             or proteasome inhibitors.

          6. Known allergy to any component of vorinostat. Prior hypersensitivity reaction of CTCAE
             Grade &gt; 3 to therapy containing propylene glycol or ethanol.

          7. Pregnant or breast-feeding women.

          8. Concurrent, active secondary malignancy for which the patient is receiving therapy.

          9. Significant active infection.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>22</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,WA</recruitmentstate>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>The Queen Elizabeth Hospital - Woodville South</hospital>
    <hospital>Sir Charles Gairdner Hospital and University of Western Australia - Nedlands</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5011 - Woodville South</postcode>
    <postcode>6009 - Nedlands</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Triphase Research and Development I Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a clinical trial examining the safety, pharmacokinetics, pharmacodynamics and
      efficacy of IV NPI-0052 (a proteasome inhibitor) in combination with oral vorinostat
      (Zolinza; a HDAC inhibitor) in patients with non-small cell lung cancer, pancreatic cancer,
      melanoma or lymphoma. Proteasome inhibitors block the breakdown of proteins by cells and HDAC
      inhibitors block modification of proteins regulating gene expression in cells. Both of these
      actions preferentially affect cancer cells, and the combination of the two has been seen to
      have a greater effect in laboratory studies.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00667082</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Steven D Reich, MD</name>
      <address>Triphase Research and Development I Corp</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>